Healthcare Advertising Compliance Review (Before Filing or Release)
If a healthcare promotion looks finished but its claims, professional identity, patient material or release route have not been tested separately, Care Journey can structure a pre-release compliance review. The clinic receives a documented view of what can proceed, what needs revision and what requires specialist or regulator review before release.
A polished healthcare ad can still fail the important tests
Platform-ready design is not the same as healthcare-advertising readiness. DHA’s professional-conduct standard says covered advertising, promotional material and public communications must be truthful, evidence-based and verifiable, and it also requires disclosure of known risks or limitations while prohibiting deceptive claims and exaggeration. (DHA Code of Ethics and Professional Conduct) A compliance review therefore starts with the claim ceiling and evidence, not the creative polish.
Start with what the strongest claim is allowed to say
- Identify the advertiser, practitioner, service or product that the creative presents.
- Extract the material healthcare claims before editing tone, layout or persuasion.
- Match those claims to the evidence available to support them and note important limitations.
- Check whether the language implies certainty, superiority or outcomes that the evidence does not support.
- Inspect patient, staff or other identifiable-person content for purpose and data-minimization questions.
- Record the jurisdiction, medium and current standard or circular version used for the review.
- Separate content-risk findings from the later licence-submission task.
- Mark unresolved legal applicability, evidence or data-use questions for escalation instead of guessing.
UAE personal-data law requires processing for a specific and clear purpose and limits personal data to what is necessary for that purpose. (UAE personal data protection framework) That creates a distinct review boundary when advertising uses identifiable patients, staff or health-related information; a copy edit cannot resolve a data-governance question by itself.
Turn review findings into release states
- Freeze the asset under review so findings can be tied to one identifiable version.
- Test identity and service representation before debating persuasive wording.
- Test the strongest material claims against available evidence and required limitations.
- Review creative/data handling as a separate control where identifiable people or health-related information appear.
- Record the governing jurisdiction, medium and current rule version used for the review.
- Assign each finding a state: pass, revise, hold, route or escalate.
- Re-review only the changed risk areas while preserving the original finding trail.
- Hand a materially resolved asset to the applicable submission or publication owner.
What This Covers and What Is Separate
The review examines claim support, practitioner and clinic identity, patient or testimonial material, necessary context, data handling and the applicable filing or release route. MOHAP states that holding its health-advertisement licence does not remove other applicable requirements. (MOHAP health-advertising licensing service) The review provides a documented pre-release assessment; it does not issue the licence or replace the authority’s decision, and legal advice remains separate.
- Do not describe the review as regulator approval or guaranteed compliance.
- Do not use it as a substitute for health-advertisement licence submission where a submission is required.
- Do not publish one fixed checklist as though it applies unchanged across every emirate, medium and claim type.
- Do not convert unresolved legal applicability into an internal “pass.”
- Do not let design quality substitute for evidence behind a medical or service claim.
- Do not expose internal review quantities, rates, schedules, package BOMs or public prices.
- Do not absorb media buying, campaign production or regulator-response handling into this service.
Questions about healthcare advertising compliance review
The review is useful before release because it creates a documented decision about what is supportable, what needs revision and what must be routed elsewhere. It should reduce ambiguity—not disguise it.
It tests separate control lanes such as advertiser/service identity, claims and evidence, creative/data handling, and jurisdiction or release routing so a pass in one area does not hide a problem in another.
No. It is a pre-release advertising-content risk review. Legal determinations and regulator decisions remain with qualified counsel or the competent authority.
No. DHA’s current professional standard requires covered advertising to be truthful, evidence-based and verifiable; creative polish does not replace claim support.
The research did not find one authoritative checklist that applies unchanged across every emirate, medium, service, product and claim type. The review should record the actual jurisdiction and current rule set used.
It should be marked as hold or escalate, with the unresolved evidence, data-use or jurisdiction issue made explicit instead of being converted into an assumed pass.
After material content risks are resolved enough for the team to identify the applicable route and prepare the controlled version and case-specific evidence for filing.
Reach a Clear Pre-Release Compliance Decision
Begin by describing the asset, its destination and the review question; do not send patient-identifiable material in the initial enquiry. Care Journey can explain the evidence and authority inputs needed for a formal review.